Home | Contact Us | Newsletter | Usersclub | Books | Audio Seminars


 

62 New Usersclub Additions

- 19 SOPs
- 21 Examples/Checklists
- 8 Forms/Templates
- 2 Master Plans
- 12 Warning Letters 

last update
August 3, 2018

 

Online Audio Seminars come with 10+ Best Practice guides for easy implementation

 

 

Validation and Control of Excel Spreadsheets for FDA Compliance
Understand requirements and get tool kits for easy implementation

Recorded, available at any time

 

Quality by Design (QbD) for Development and Validation of Analytical Methods

With focus on the analytical lifecycle
Recorded, available at any time

 

FDA Compliant IT Infrastructure and Network Qualification 

With Strategies and Tool Kit for Compliance and System Uptime

Recorded, available at any time

 

Ensuring Data Integrity for FDA/EU Compliance
Comply with FDA Part 11 and EU/PICS Annex 11 for paper, electronic and hybrid records
Recorded, available at any time

 

Understanding the new Revision of USP <1058> 
With examples and procedures for effective implementation

Recorded, available at any time

 

Understanding the New FDA Guidance for Validation of Analytical Methods

With 10+ best practice guides for easy implementation

Recorded, available at any time

 

Learning from Recent Warning Letters related to Part 11 and Computer Validation

With Clear Recommendations for Corrective and Preventive Actions

Recorded, available at any time

 

Transfer of Analytical Methods According to New FDA, USP and EU-GMP Guidelines
With SOPs, templates and examples for easy implementation
Recorded, available at any time

 

Validation and Use of Cloud Computing in FDA Regulated Environments

Comply with GXPs, Part 11, EU Annex 11 and other regulations

Recorded, available at any time

 

Understanding the New FDA Data Integrity Guidance
With examples and procedures for effective implementation

June 22, 2017

 

Contingency and Disaster Recovery Planning for Computer Systems
To Ensure Business Continuity and Compliance
June 26, 2017

 

Analytical Instrument Qualification According the new Revision of
USP <1058> 

With SOPs, Templates and Examples for easy Implementation
Recorded, available at any time

 

FDA/EU Compliant Handling of OOX Test Results

Learn how to investigate out-of-trend (OOT) and out-of-expectation (OOE) vs. OOS results

Recorded

 

Understanding Quality by Design for the Pharmaceutical Industry

Introduction to Principles, Regulatory Activities and Industry Practices

Recorded, available at any time

 

Impact of Quality by Design on the Analytical Laboratory

Learn through examples on development and validation of analytical procedures

Recorded, available at any time

 

Managing Electronic Raw Data in Regulated Environments

Definition, generation, evaluation and archiving for FDA, ICH, PIC/S and EU compliance

Recorded, available on demand

 

How to Prepare Yourself for FDA's on-going Part 11 Inspection Program

Learn what the FDA is looking for and how to respond

Recorded

 

with 10+ validation  examples, seminar with FDA's Dennis Cantellops and Ludwig Huber and with 13 SOPs for easy implementation.

 

 

 

October  2018

FDA Publishes a Risk based Site Selection Model (SSM) for FDA Inspections

The document describes CDER’s Risk-Based Model with policies and procedures to prioritize manufacturing sites for routine quality-related (current good manufacturing practice (CGMP)) surveillance inspections. The number of sites assigned varies depending on FDA capacity as determined by multiyear resource planning. FDA will use the SSM to generate a risk score for each site. Scoring of risk components is based on either empirical evidence collected by FDA, subject matter experts’ judgment, or a combination of both. The following are currently identified as risk factors for inclusion in the SSM: a) Site type (e.g., manufacturer, packager only, control lab only). b) Time since last surveillance inspection (or if the site was never previously inspected). c) FDA compliance history. d) Foreign regulatory authority inspectional history (with an authority deemed capable under section 809 of the FD&C Act). e) Patient exposure. The guide can be downloaded from the FDA website.

New FDA guidance on Presenting Quantitative Efficacy and Risk Information

The draft guidance describes FDA’s recommendations for presenting quantitative effectiveness and risk information (information that numerically addresses the likelihood or magnitude of a drug’s effectiveness or risks) in direct-to-consumer (DTC) promotional labeling and advertisements for prescription human drugs and biological products and prescription animal drugs and in DTC promotional labeling for over-the-counter animal drugs. The guide can be viewed and downloaded from the FDA website.

 

New or Updated Sites

Click here to tell others in your company about compliance news

Publishers Note

PUBLISHER'S NOTE: Some of the documents presented in this News section may require registration to the Labcompliance Usersclub to access their information. At the time of the News release, all links to other websites functioned, but Labcompliance cannot guarantee the accuracy of the information and that the links will not disabled.